TISIDB

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00907 T-box PF16176 T-box transcription factor-associated
Function	Functions as a transcriptional activator playing a crucial role during development. Functions in trophoblast differentiation and later in gastrulation, regulating both mesoderm delamination and endoderm specification. Plays a role in brain development being required for the specification and the proliferation of the intermediate progenitor cells and their progeny in the cerebral cortex. Also involved in the differentiation of CD8+ T-cells during immune response regulating the expression of lytic effector genes.

> Gene Ontology [ TOP ]
Biological Process	GO:0001701 in utero embryonic development GO:0001704 formation of primary germ layer GO:0001706 endoderm formation GO:0001707 mesoderm formation GO:0001708 cell fate specification GO:0001711 endodermal cell fate commitment GO:0001714 endodermal cell fate specification GO:0001824 blastocyst development GO:0001825 blastocyst formation GO:0001829 trophectodermal cell differentiation GO:0001837 epithelial to mesenchymal transition GO:0001890 placenta development GO:0001892 embryonic placenta development GO:0002250 adaptive immune response GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002287 alpha-beta T cell activation involved in immune response GO:0002292 T cell differentiation involved in immune response GO:0002293 alpha-beta T cell differentiation involved in immune response GO:0002302 CD8-positive, alpha-beta T cell differentiation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002521 leukocyte differentiation GO:0003002 regionalization GO:0007159 leukocyte cell-cell adhesion GO:0007369 gastrulation GO:0007389 pattern specification process GO:0007492 endoderm development GO:0007498 mesoderm development GO:0007507 heart development GO:0007517 muscle organ development GO:0007519 skeletal muscle tissue development GO:0010002 cardioblast differentiation GO:0014706 striated muscle tissue development GO:0019827 stem cell population maintenance GO:0021537 telencephalon development GO:0021543 pallium development GO:0021772 olfactory bulb development GO:0021796 cerebral cortex regionalization GO:0021871 forebrain regionalization GO:0021895 cerebral cortex neuron differentiation GO:0021953 central nervous system neuron differentiation GO:0021978 telencephalon regionalization GO:0021987 cerebral cortex development GO:0021988 olfactory lobe development GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0030900 forebrain development GO:0032609 interferon-gamma production GO:0035051 cardiocyte differentiation GO:0035914 skeletal muscle cell differentiation GO:0035987 endodermal cell differentiation GO:0036037 CD8-positive, alpha-beta T cell activation GO:0042110 T cell activation GO:0043374 CD8-positive, alpha-beta T cell differentiation GO:0045165 cell fate commitment GO:0046631 alpha-beta T cell activation GO:0046632 alpha-beta T cell differentiation GO:0048332 mesoderm morphogenesis GO:0048568 embryonic organ development GO:0048608 reproductive structure development GO:0048762 mesenchymal cell differentiation GO:0048863 stem cell differentiation GO:0060485 mesenchyme development GO:0060537 muscle tissue development GO:0060538 skeletal muscle organ development GO:0060706 cell differentiation involved in embryonic placenta development GO:0060795 cell fate commitment involved in formation of primary germ layer GO:0060809 mesodermal to mesenchymal transition involved in gastrulation GO:0061458 reproductive system development GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:0098727 maintenance of cell number
Molecular Function	GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding GO:0001085 RNA polymerase II transcription factor binding GO:0001102 RNA polymerase II activating transcription factor binding GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding GO:0003682 chromatin binding GO:0008134 transcription factor binding GO:0033613 activating transcription factor binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1266738: Developmental Biology R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation R-HSA-452723: Transcriptional regulation of pluripotent stem cells

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EOMES and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between EOMES and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
22544698	Lymphoma	Promote immunity (NK cell function)	Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.
27775550	Acute myeloid leukemia	Promote immunity	Indeed, NK cells from leukemic mice and humans with AML showed lower levels of TBET and EOMES, transcription factors that are critical for terminal NK cell differentiation.
19688743	Melanoma	Promote immunity (T cell function)	Gadd45b, a signaling molecule highly up-regulated during Th1 type responses, is studied for its role in limiting tumor growth. Mouse B16 melanoma cells implanted into Gadd45b(-/-) mice grew faster than those in WT or Gadd45b(+/-) littermate controls. The defect of Gadd45b(-/-) mice in tumor immunosurveillance was attributed to the reduced expression of IFN-gamma, granzyme B, and CCR5 in Gadd45b(-/-) CD8(+) T cells at the tumor site. Activation of p38 MAP kinase, but not ERK or JNK, by either TCR-stimuli or IL-12 and IL-18 is diminished in Gadd45b(-/-) CD8(+) T cells, resulting in reduced production of IFN-gamma. In addition, mRNA of T-bet and Eomes were reduced in Gadd45b(-/-) CD8(+) T cells, supporting a critical role of Gadd45b in shaping the Th1 fate.
20713880	Melanoma	Promote immunity (infiltration)	In this paper, we show that the combined germline deletion of T-bet and T cell-specific deletion of Eomes resulted in profound defects in adaptive antitumor immune responses. T-bet and Eomes drive Tc1 differentiation by preventing alternative CD8(+) T cell differentiation to Tc17 or Tc2 cells. Surprisingly, T-bet and Eomes are not critical for the generation of systemic CTL activities against cancer cells. Instead, T-bet and Eomes are crucial for tumor infiltration by CD8(+) T cells.
18523263	Melanoma	Promote immunity	Antitumor responses depend on type 1 immunity, which is severely impaired in mice deficient for the T-box expressed in T cells (T-bet) transcription factor. Both T-bet-deficient (T-bet(-/-)) NK and CTL show defective function, which can be overcome by strong stimuli due to the expression of eomesodermin, another member of the T-box family.
20525896	Melanoma	Promote immunity (T cell function)	Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin. Indeed, CD44(high) Vgamma4 gammadelta T cells produced significantly more IFN-gamma and perforin on activation, and showed greater cytolytic activity than did CD44(high) Vgamma1 gammadelta T cells, apparently due to the high level of eomesodermin (Eomes) in these activated Vgamma4 gammadelta T cells. Consistently, transfection of dominant-negative Eomes in Vgamma4 gammadelta T cells diminished the level of IFN-gamma secretion, indicating a critical role of Eomes in the effector function of these gammadelta T cells.

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EOMES in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EOMES in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.179	0.696
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.879	0.392
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.326	0.663
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.281	0.603
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.664	0.542
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.201	0.878
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.402	0.372
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.738	0.416
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.067	0.951
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.002	0.286
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.428	0.751
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.407	0.103

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EOMES in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	5.5	-1.8	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	6.8	-3.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EOMES. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EOMES. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EOMES. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EOMES. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EOMES expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EOMES and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EOMES
Name	eomesodermin
Aliases	TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location	3p24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EOMES collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EOMES